Peptide Purity Testing: Third-Party COAs Explained

A first-party COA is produced by the manufacturer of the peptide. A second-party COA is produced by the buyer or distributor of the peptide. A third-party COA is produced by a laboratory operationally independent from both — no shared ownership, no commercial incentive to over-report purity, no pressure to release a batch that does not meet the specification.

Janoshik Analytical is the most widely cited third-party laboratory in European research-peptide supply. Anresco, Auriga Research and several university-hosted core facilities also operate at the third-party standard. Supplier-internal laboratories — even when technically competent — are not third-party regardless of the analytical quality of their output.

An independent laboratory has no commercial reason to report a higher purity than the batch contains, to under-report related impurities, or to release a batch that fails specification. A supplier-funded internal laboratory has all three of those incentives, even when its analysts are scrupulous. That difference in incentive structure is the entire reason a third-party COA carries more weight.

The point is not that supplier-internal laboratories are dishonest — most are competent and many are scrupulous. The point is that the buyer cannot tell the difference from the outside, and the incentive structure tilts the room. Independence removes the tilt.

Look at four fields: (1) the laboratory name — is it named, and is it the same company as the supplier? (2) the laboratory address — is it published, and is it a different address from the supplier? (3) the analyst signature — is it a named analyst from the laboratory, not a supplier employee? (4) the report formatting — does it look like every other report from the same independent laboratory across the industry, or has it been re-typeset by the supplier?

A supplier-internal COA dressed as third-party will typically fail on at least two of those four. A genuine third-party COA passes all four cleanly. If you cannot tell from the COA itself, ask the supplier directly — and treat the answer as data.

A verified supplier's release rule is straightforward: a batch without an independent third-party COA does not ship. Janoshik Analytical is the default verifier; an orthogonal independent laboratory is used when batch chemistry calls for a second method or when the receiving institution requires a specific accredited laboratory.

The rule exists because the alternative — accepting supplier-internal COAs to keep supply flowing — exposes the receiving researcher to a tilted incentive structure they cannot inspect. A well-run supplier would rather delay a batch than ship without independent verification.

Third-party analytical testing covers identity, purity, related impurities and water content for the analysed sample. It does not cover sterility (a separate test), endotoxin (a separate test), residual solvents (a separate test), genotoxic impurities (a separate test) or biological activity (a separate assay). For research-grade in-vitro use the standard third-party COA is sufficient; for sensitive protocols additional testing should be commissioned through the supplier.

A verified supplier can add sterility, endotoxin and residual-solvent analysis on request. The standard third-party COA is shipped on every batch by default.

One underrated benefit of third-party testing is cross-batch comparability. When every batch of a given compound is verified by the same independent laboratory under the same method, the receiving researcher can compare a current batch's purity, related-impurities profile and water content against the previous batch — and notice drift before it affects an experiment.

A verified supplier maintains the published history of independent COAs in its public COA archive exactly so that institutional buyers can audit cross-batch consistency before committing to a multi-batch programme.

If a supplier refuses to provide an independent third-party COA — or only provides an internal report — treat that as a sourcing flag. There are legitimate reasons a batch might be temporarily without a fresh third-party COA (queue at the laboratory, paperwork lag, recent dispatch), but the refusal pattern should not persist across multiple batches.

A verified supplier's position is that every batch ships with the independent COA bundled, printed and electronic. If a research project cannot move forward without verification, the consultations team will hold dispatch until the report is in hand rather than ship blind.

Independent third-party testing is the credibility baseline for research-peptide supply. It is not a premium feature, it is not a marketing claim — it is the minimum analytical evidence a buyer needs to commit a batch to a protocol with confidence. Suppliers that operate to the third-party standard make that clear in their batch documentation; suppliers that do not, signal their position by what is absent from their COA.

Read the COA, check the four laboratory-identity fields, and treat the answer as data. A verified supplier structures every batch around exactly that workflow.

Falsified medical products, a global threat first brought to public attention by the World Health Organization (WHO) in 1985, pose significant risks to patient safety (PMID 30165334). The estimated annual death toll from falsified medical products ranges from two hundred thousand to one million globally (PMID 30165334). While the issue is most pronounced in developing nations, a substantial black market for these products has also emerged in the developed world (PMID 30165334).

In recent years, biotechnology drugs, including synthetic peptide drugs and protein drugs, have increasingly become targets for falsification (PMID 30165334). This includes substances traditionally associated with doping or image enhancement, such as human growth hormone and melanotan II, as well as essential medicines like insulin, oxytocin, and monoclonal antibodies (PMID 30165334). The danger in using these falsified polypeptide drugs lies in the absence of guarantees regarding their safety and efficacy for end-users (PMID 30165334).

Reports have detailed issues such as the presence of the wrong active pharmaceutical ingredient (API), incorrect dosages, or the complete absence of the API in falsified products (PMID 30165334). Adverse health effects have been linked to toxic contaminations and impurities (PMID 30165334). Furthermore, regulatory agencies have seized unauthorized polypeptides or those that have failed or are still undergoing clinical or preclinical trials (PMID 30165334).

Concerns about the quality of therapeutic peptides extend to critical medications. For example, oxytocin, vital for preventing and treating postpartum hemorrhage (a major cause of maternal death), has been found to be of poor quality in low- and middle-income countries (LMIC) (PMID 27006180). A systematic review of studies in LMIC revealed that a median of 45.6% of oxytocin samples failed quality tests, with ranges between 0-80% (PMID 27006180). These failures were primarily due to insufficient amounts of the active pharmacological ingredient (PMID 27006180).

Over one-third of the oxytocin samples (204 out of 559) had less than 90% oxytocin content, indicating substandard medicine; two samples contained no active ingredient at all, suggesting they were counterfeit (PMID 27006180). The proportion of low-quality oxytocin was higher in Africa (57.5%) compared to Asia or Latin America (22.3% and 0%, respectively, P < 0.0001) (PMID 27006180). It was also higher in the private sector (34.0%) versus the public sector (25.3%, P = 0.032) and at facility levels (37.9%) compared to central distributors (22.0%, P = 0.030) (PMID 27006180).

Similar concerns exist for insulin. Post-marketing discovery of subpotent, superpotent, contaminated, or mislabeled biosimilar insulin necessitates its quarantining and removal (PMID 25172881). Such products could be considered 'counterfeit' if they do not meet established FDA standards (PMID 25172881). The FDA could establish regular assaying of biosimilar insulin samples from the supply pipeline to ensure patient safety and evaluate clinical performance (PMID 25172881). Independent groups could perform confidential comparison assays (PMID 25172881).

The online availability of prescription-only biologic drugs like somatropin presents considerable risks. Websites promoting somatropin for performance enhancement or body improvement make these injections accessible without medical prescription, encouraging misuse (PMID 27888454). Customers purchasing parenteral medications online risk their health due to potentially unprofessional distribution and handling (PMID 27888454).

A study evaluating the online market for no-prescription somatropin products found that 17 individual Internet vendor websites distributed these products directly to patients (PMID 27888454). The majority (94%) of these sites did not require a valid medical prescription before dispensing (PMID 27888454). Furthermore, most (70%) displayed no medical information, and none (0%) showed any regulatory body logo (PMID 27888454).

Analysis of online somatropin samples revealed significantly lower somatropin concentrations than labeled (p < 0.001) (PMID 27888454). This suggests that online distribution and handling practices likely lead to degradation of the product, posing potential patient safety concerns (PMID 27888454).

The quality of therapeutic proteins, including hormones, subunit vaccines, conjugate vaccines, and antibodies, is crucial for both safety and efficacy in modern medicine (PMID 29572496). Identifying malformed proteins at the point-of-care can prevent adverse immune reactions in patients (PMID 29572496). This is particularly important when insecure supply chains could lead to the delivery of degraded or counterfeit drug products (PMID 29572496).

Research has demonstrated the identification of degraded protein, such as human growth hormone, by utilizing automated anomaly detection algorithms (PMID 29572496). This method diverges from previous applications of machine learning to spectral analysis by constructing the classifier using only example spectra of genuine, high-quality drug products (PMID 29572496).

The algorithm was tested on Raman spectra of protein dilutions typical of formulated drug products, using sample volumes of 25 µL, which is less than typical overfill waste volumes in injectable drug product vials (PMID 29572496). The algorithm successfully classified anomalous recombinant human growth hormone (rhGH) with 92% sensitivity and 98% specificity, even when it had only been previously exposed to high-quality drug product (PMID 29572496).

Regulatory agencies and analytical laboratories face significant challenges in analyzing falsified biotechnology drugs and their potential impurities (PMID 30165334). The analytical process is often complex due to the differences in size and complexity among peptides, proteins, and monoclonal antibodies (PMID 30165334).

Laboratories frequently rely on a combination of techniques, including electrophoretic methods, immunological assays, and mass spectrometry-based approaches, to identify the content of seized samples (PMID 30165334). For instance, capillary electrophoresis with UV detection and electrospray ionization mass spectrometry has been used to investigate somatropin content (PMID 27888454).

Furthermore, methods like Capillary Electrophoresis-Ultraviolet-Mass Spectrometry (CE-UV-MS) have been described for the simultaneous determination and quantification of insulin in pharmaceutical formulations (PMID 27473491). This method, validated according to international guidelines, has demonstrated the ability to quantify insulin within a ±5% acceptance range and can be applied in quality control and counterfeit detection (PMID 27473491). Similarly, micellar electrokinetic chromatography (MEKC) has been developed for the simultaneous determination of human insulin, its analogues, main degradation products, and excipients in injection formulations, with a rapid analysis time of 3 minutes (PMID 25599910).

Substances initially developed for therapeutic use are often misused by athletes as doping agents and for image-enhancement outside regulated sports, fostering a market for counterfeit doping substances (PMID 28156209). These counterfeit doping agents often exhibit poor pharmaceutical quality, posing significant health risks to consumers (PMID 28156209).

A study investigated the pharmaceutical quality of 1,190 doping products seized at the Swiss border by Swiss customs authorities (PMID 28156209). The primary analytical methods employed for characterizing confiscated compounds included liquid chromatography-high resolution mass spectrometry, polyacrylamide gel electrophoresis with in-gel tryptic digestion and nanoliquid chromatography-tandem mass spectrometry for peptidic compounds, and electrochemiluminescence immunoassay (PMID 28156209).

The study found that for 889 (75%) of the analyzed products, the label suggested anabolic agents, for 146 samples (12%) peptide hormones or growth factors, and for 113 items (9%) antiestrogens, aromatase inhibitors, or other metabolic modulators (PMID 28156209). However, the pharmaceutical quality of most products was unsatisfactory; non-approved substances were detected, and less than 20% of the products contained the claimed substance in the specified amount (PMID 28156209). This alarming number of substandard products highlights ongoing challenges in sports drug testing and underscores the importance of stringent quality verification (PMID 28156209).

• Optical Detection of Degraded Therapeutic Proteins. — Scientific reports (2018). PMID 29572496
• Falsification of biotechnology drugs: current dangers and/or future disasters? — Journal of pharmaceutical and biomedical analysis (2018). PMID 30165334
• Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature. — BJOG : an international journal of obstetrics and gynaecology (2016). PMID 27006180
• Qualitative and Semiquantitative Analysis of Doping Products Seized at the Swiss Border. — Substance use & misuse (2017). PMID 28156209
• Capillary Electrophoresis-Ultraviolet-Mass Spectrometry (CE-UV-MS) for the Simultaneous Determination and Quantification of Insulin Formulations. — Methods in molecular biology (Clifton, N.J.) (2016). PMID 27473491
• Availability and quality of illegitimate somatropin products obtained from the Internet. — International journal of clinical pharmacy (2017). PMID 27888454
• Simultaneous determination of insulin and its analogues in pharmaceutical formulations by micellar electrokinetic chromatography. — Journal of pharmaceutical and biomedical analysis (2015). PMID 25599910
• FDA-approved biosimilar insulin: good enough for critical care, adulterated, or counterfeit? How can we tell? — Journal of diabetes science and technology (2014). PMID 25172881